Xencor Lowers Revenue Outlook for Ultomiris Royalties
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy AZN?
Source: Benzinga
- Revenue Outlook Revision: Xencor Inc. announced a revision of its revenue outlook for royalties tied to Ultomiris, as Alexion Pharmaceuticals stated it does not owe additional royalties on Ultomiris sales, which will directly impact Xencor's future cash flow and profitability.
- Cash Flow Forecast Adjustment: Xencor lowered its 2026 cash outlook from $400 million–$430 million to $380 million–$400 million, although it still expects its cash runway to support operations into mid-2028, indicating some financial pressure on the company.
- Analyst Perspective: William Blair holds a slightly negative view on Xencor's outlook, yet anticipates that clinical trial updates in 2026 will serve as more impactful catalysts, thus reiterating an Outperform rating, reflecting cautious optimism about the company's long-term potential.
- Technical Analysis Signals: Xencor's stock is currently trading below its 20-day and 100-day simple moving averages, indicating short-term weakness; despite an 83% increase in share price over the past 12 months, the mixed signals from RSI and MACD suggest investors should proceed with caution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 186.680
Low
157.61
Averages
213.64
High
252.18
Current: 186.680
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AstraZeneca Set to Release Q1 Earnings on April 29
- Earnings Announcement: AstraZeneca is set to announce its Q1 earnings on April 29 before market open, with consensus EPS estimates at $1.27 and revenue projections at $14.92 billion, providing crucial insights into the company's financial health for investors.
- Solid Growth Outlook: Despite market challenges, AstraZeneca's overall growth outlook remains solid, with improving margins and returns indicating the company's potential for sustained development in the competitive pharmaceutical industry.
- China Market Strategy: AstraZeneca's investment in the Chinese market is viewed as a key strategy, as the increasing demand for innovative drugs in China positions the company to capture a larger share of this rapidly growing market.
- New Drug Approval Progress: AstraZeneca's Breztri has received U.S. approval for asthma treatment, and the company is also seeking accelerated approval for Ultomiris in IgA nephropathy, which will further enhance its product portfolio and drive future revenue growth.
See More
AstraZeneca Q1 Earnings Exceed Expectations
- Earnings Beat: AstraZeneca reported a Q1 non-GAAP EPS of $2.58, surpassing expectations by $1.31, which underscores the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved revenues of $15.29 billion, reflecting a 12.5% year-over-year increase, exceeding market expectations by $370 million, indicating AstraZeneca's sustained competitiveness in the global market.
- Core Operating Profit Increase: Core operating profit rose by 12% with a core tax rate of 21%, demonstrating successful cost control and operational efficiency, which is expected to positively impact future financial performance.
- Stable Future Outlook: AstraZeneca reaffirmed its total revenue and core EPS guidance for FY 2026, anticipating mid-to-high single-digit revenue growth and low double-digit core EPS growth, reflecting the company's confidence in future growth prospects.
See More
FDA Launches Pilot Program for AI-Driven Drug Development
- Real-Time Trials Initiated: The FDA has announced that Amgen and AstraZeneca have initiated real-time clinical trials aimed at accelerating drug development through AI and data science, which is expected to significantly shorten drug approval timelines and enhance patient access to new therapies.
- Pilot Program Context: The FDA plans to launch a pilot program this summer based on learnings from proof-of-concept studies targeting cancer therapies, indicating a strong commitment from regulators to innovate drug development processes by soliciting public input to refine the initiative.
- AstraZeneca's Trial Progress: AstraZeneca's Phase 2 trial, TRAVERSE, is testing its anticancer drug acalabrutinib as a combination therapy for treatment-naïve mantle cell lymphoma, showcasing the company's ongoing investment and innovation in cancer treatment.
- Amgen's Site Selection: Amgen is currently selecting sites for its Phase 1b trial, STREAM-SCLC, targeting patients with limited-stage small cell lung carcinoma, with real-time reporting of critical findings expected to accelerate promising therapies and support continuous drug development advancements.
See More
PARADIGM HEALTH: AMGEN AND ASTRAZENECA PIONEER THIS COLLABORATION
Collaboration Announcement: Paradigm Health has announced a new collaboration with AstraZeneca, marking a significant partnership in the healthcare sector.
Focus on Innovation: The collaboration aims to leverage both companies' strengths to drive innovation in health solutions and improve patient outcomes.
See More
AstraZeneca's Breztri Approved for Asthma Treatment
- New Drug Approval: AstraZeneca's fixed-dose triple-combination therapy, Breztri Aerosphere, has received FDA approval for the maintenance treatment of asthma in patients aged 12 and older, marking a significant advancement in the company's respiratory disease portfolio.
- Market Potential: Breztri combines the efficacy of corticosteroid/long-acting beta2-agonist with a long-acting muscarinic antagonist, which is expected to attract a large patient base, especially as existing dual maintenance therapies still pose risks for exacerbations.
- Patient Needs: Despite the availability of dual maintenance therapy, many patients continue to face exacerbation risks and daily breathing difficulties, and the FDA approval provides new hope for these individuals to improve their respiratory conditions sooner.
- Global Impact: Breztri was prescribed to over 6.8 million patients globally in 2025, demonstrating its widespread use among chronic obstructive pulmonary disease patients, and this approval is anticipated to further enhance its penetration in the asthma market.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
AstraZeneca Set to Release Q1 Earnings on April 29
- Earnings Announcement: AstraZeneca is set to announce its Q1 earnings on April 29 before market open, with consensus EPS estimates at $1.27 and revenue projections at $14.92 billion, providing crucial insights into the company's financial health for investors.
- Solid Growth Outlook: Despite market challenges, AstraZeneca's overall growth outlook remains solid, with improving margins and returns indicating the company's potential for sustained development in the competitive pharmaceutical industry.
- China Market Strategy: AstraZeneca's investment in the Chinese market is viewed as a key strategy, as the increasing demand for innovative drugs in China positions the company to capture a larger share of this rapidly growing market.
- New Drug Approval Progress: AstraZeneca's Breztri has received U.S. approval for asthma treatment, and the company is also seeking accelerated approval for Ultomiris in IgA nephropathy, which will further enhance its product portfolio and drive future revenue growth.
See More
AstraZeneca Q1 Earnings Exceed Expectations
- Earnings Beat: AstraZeneca reported a Q1 non-GAAP EPS of $2.58, surpassing expectations by $1.31, which underscores the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved revenues of $15.29 billion, reflecting a 12.5% year-over-year increase, exceeding market expectations by $370 million, indicating AstraZeneca's sustained competitiveness in the global market.
- Core Operating Profit Increase: Core operating profit rose by 12% with a core tax rate of 21%, demonstrating successful cost control and operational efficiency, which is expected to positively impact future financial performance.
- Stable Future Outlook: AstraZeneca reaffirmed its total revenue and core EPS guidance for FY 2026, anticipating mid-to-high single-digit revenue growth and low double-digit core EPS growth, reflecting the company's confidence in future growth prospects.
See More
FDA Launches Pilot Program for AI-Driven Drug Development
- Real-Time Trials Initiated: The FDA has announced that Amgen and AstraZeneca have initiated real-time clinical trials aimed at accelerating drug development through AI and data science, which is expected to significantly shorten drug approval timelines and enhance patient access to new therapies.
- Pilot Program Context: The FDA plans to launch a pilot program this summer based on learnings from proof-of-concept studies targeting cancer therapies, indicating a strong commitment from regulators to innovate drug development processes by soliciting public input to refine the initiative.
- AstraZeneca's Trial Progress: AstraZeneca's Phase 2 trial, TRAVERSE, is testing its anticancer drug acalabrutinib as a combination therapy for treatment-naïve mantle cell lymphoma, showcasing the company's ongoing investment and innovation in cancer treatment.
- Amgen's Site Selection: Amgen is currently selecting sites for its Phase 1b trial, STREAM-SCLC, targeting patients with limited-stage small cell lung carcinoma, with real-time reporting of critical findings expected to accelerate promising therapies and support continuous drug development advancements.
See More
PARADIGM HEALTH: AMGEN AND ASTRAZENECA PIONEER THIS COLLABORATION
Collaboration Announcement: Paradigm Health has announced a new collaboration with AstraZeneca, marking a significant partnership in the healthcare sector.
Focus on Innovation: The collaboration aims to leverage both companies' strengths to drive innovation in health solutions and improve patient outcomes.
See More
AstraZeneca's Breztri Approved for Asthma Treatment
- New Drug Approval: AstraZeneca's fixed-dose triple-combination therapy, Breztri Aerosphere, has received FDA approval for the maintenance treatment of asthma in patients aged 12 and older, marking a significant advancement in the company's respiratory disease portfolio.
- Market Potential: Breztri combines the efficacy of corticosteroid/long-acting beta2-agonist with a long-acting muscarinic antagonist, which is expected to attract a large patient base, especially as existing dual maintenance therapies still pose risks for exacerbations.
- Patient Needs: Despite the availability of dual maintenance therapy, many patients continue to face exacerbation risks and daily breathing difficulties, and the FDA approval provides new hope for these individuals to improve their respiratory conditions sooner.
- Global Impact: Breztri was prescribed to over 6.8 million patients globally in 2025, demonstrating its widespread use among chronic obstructive pulmonary disease patients, and this approval is anticipated to further enhance its penetration in the asthma market.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
